NEU 0.57% $12.35 neuren pharmaceuticals limited

Read the FDA Advice here -...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 502 Posts.
    lightbulb Created with Sketch. 457
    Read the FDA Advice here - https://www.fda.gov/media/136238/download

    First impressions suggest that the release by the FDA is for guidance only. The Co. will need to establish whether the trial efficacy will be affected by the plethora of COVID-19 circumstances. For example; pertaining to travel, schedules, on-site monitoring requirements etc... However, the advice states....

    "In general, FDA’s guidance documents, including this guidance, do not establish legally
    enforceable responsibilities.
    Instead, guidances describe the Agency’s current thinking on a topic
    and should be viewed only as recommendations, unless specific regulatory or statutory
    requirements are cited. The use of the word should in Agency guidance means that something is
    suggested or recommended, but not required. "

    Point 2 - Sponsors, in consultation with clinical investigators and Institutional Review Boards
    (IRBs)/Independent Ethics Committees (IECs), may determine that the protection of a
    participant’s safety, welfare, and rights is best served by continuing a study participant
    in the trial as per the protoco
    l or by discontinuing the administration or use of the
    investigational product or even participation in the trial. Such decisions will depend on
    specific circumstances, including the nature of the investigational product, the ability to
    conduct appropriate safety monitoring, the potential impact on the investigational
    product supply chain, and the nature of the disease under study in the trial.


    I believe the team will be reviewing the circumstances of the trials over the coming days to determine whether the efficacy of the trials will be affected.

    I'd hate for the team to proceed with the trials for the information/results to be discredited at the back-end, only then having to repeat the trials under more certain circumstances.
    Last edited by koldkathode1: 20/03/20
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$12.35
Change
0.070(0.57%)
Mkt cap ! $1.578B
Open High Low Value Volume
$12.25 $12.45 $12.02 $7.808M 638.6K

Buyers (Bids)

No. Vol. Price($)
1 41 $12.35
 

Sellers (Offers)

Price($) Vol. No.
$12.37 1579 2
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.